Eight stock picks to play one of the healthiest corners of the market

The healthcare sector of the U.S. stock market as a whole is cheaply priced, which can make it attractive to investors concerned that the S&P 500 has gotten too expensive several years into a bull market.

Market Watch • Dec 11, 2025

Here is Why Growth Investors Should Buy Insulet (PODD) Now

Insulet (PODD) is well positioned to outperform the market, as it exhibits above-average growth in financials.

Zacks Investment Research • Dec 10, 2025

PODD Stock Benefits From FDA Approval of Omnipod 5's Enhancements

Insulet Stock rises as the FDA clears key Omnipod 5 upgrades that enhance glucose targets and automation for its tubeless diabetes platform.

Zacks Investment Research • Dec 8, 2025

Here's Why Insulet (PODD) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research • Dec 4, 2025

Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it has received FDA 510(k) clearance for significant enhancements to the Omnipod 5 Automated Insulin Delivery System. These updates to the Omnipod 5 algorithm set a new benchmark in tubeless diabetes technology by offering a lower 100 mg/dL Target Glucose option and a more seamless automated experie.

Business Wire • Dec 4, 2025

Artisan International Small-Mid Fund Q3 2025 Contrarianism Pays Off

Our philosophy often runs counter to prevailing market sentiment, especially in times of excessive concentration and narrow market leadership. During this time, when many investors saw insulin pumps as “GLP-1 losers,” we acquired a position in Insulet (PODD) and added to our position in ConvaTec (CNVVY). We acquired shares of SolarEdge on the day the Trump administration began to review the Biden agenda.

Seeking Alpha • Nov 26, 2025

Looking for a Growth Stock? 3 Reasons Why Insulet (PODD) is a Solid Choice

Insulet (PODD) could produce exceptional returns because of its solid growth attributes.

Zacks Investment Research • Nov 24, 2025

Insulet Corporation (PODD) Analyst/Investor Day Transcript

Insulet Corporation ( PODD ) Analyst/Investor Day November 20, 2025 9:00 AM EST Company Participants Clare Trachtman - Vice President of Investor Relations Ashley McEvoy - CEO, President & Director Eric Benjamin - Executive VP & COO Trang Ly - Senior VP & Chief Medical Officer Manoj Raghunandanan - Senior VP & Chief Growth Officer Carolyn Sleeth - Senior Vice President of Global Commercial Capabilities & U.S. General Manager Flavia Pease - Executive VP & CFO Conference Call Participants Michael Conway Matthew O'Brien - Piper Sandler & Co., Research Division Robert Marcus - JPMorgan Chase & Co, Research Division Travis Steed - BofA Securities, Research Division David Roman - Goldman Sachs Group, Inc., Research Division Larry Biegelsen - Wells Fargo Securities, LLC, Research Division Jeffrey Johnson - Robert W. Baird & Co. Incorporated, Research Division Joanne Wuensch - Citigroup Inc., Research Division Danielle Antalffy - UBS Investment Bank, Research Division Michael Polark - Wolfe Research, LLC Christopher Pasquale - Nephron Research LLC Issie Kirby - Rothschild & Co Redburn, Research Division Joshua Jennings - TD Cowen, Research Division Presentation Clare Trachtman Vice President of Investor Relations Good morning, everyone, and welcome to Insulet's 2025 Investor Day.

Seeking Alpha • Nov 21, 2025

Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (“Insulet” or the “Company”), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today hosted its 2025 Investor Day at the Company's global headquarters in Acton, Massachusetts. During the event, Insulet's executive team outlined the strategic plan and innovation roadmap that is designed to extend its leadership in the fast-growing and significantly underpenetrated global markets for automa.

Business Wire • Nov 20, 2025

3 Stocks With Upgraded Broker Ratings to Buy for Solid Returns

Upgraded broker ratings bring the spotlight to PODD, SNDK and OI as potential picks in a selective market, each showing strong earnings growth and momentum.

Zacks Investment Research • Nov 20, 2025